MAPK1 and COVID-19: Finally, RELA, TNF, IL-6, IL-8, MAPK14, TP53, CXCL8, MAPK3, MAPK1, IL-4, MAPK8, CASP8, and STAT1 were declared key targets of HSBD for the treatment of severe COVID-19 patients (Zhu et al., 2021).